These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 19495754)

  • 1. Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.
    Azzariti A; Porcelli L; Simone GM; Quatrale AE; Colabufo NA; Berardi F; Perrone R; Zucchetti M; D'Incalci M; Xu JM; Paradiso A
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):335-46. PubMed ID: 19495754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substrate-dependent bidirectional modulation of P-glycoprotein-mediated drug resistance by erlotinib.
    Noguchi K; Kawahara H; Kaji A; Katayama K; Mitsuhashi J; Sugimoto Y
    Cancer Sci; 2009 Sep; 100(9):1701-7. PubMed ID: 19493273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
    Jovelet C; Bénard J; Forestier F; Farinotti R; Bidart JM; Gil S
    Eur J Pharm Sci; 2012 Aug; 46(5):484-91. PubMed ID: 22484209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
    Yanase K; Tsukahara S; Asada S; Ishikawa E; Imai Y; Sugimoto Y
    Mol Cancer Ther; 2004 Sep; 3(9):1119-25. PubMed ID: 15367706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.
    Hegedüs C; Truta-Feles K; Antalffy G; Várady G; Német K; Ozvegy-Laczka C; Kéri G; Orfi L; Szakács G; Settleman J; Váradi A; Sarkadi B
    Biochem Pharmacol; 2012 Aug; 84(3):260-7. PubMed ID: 22548830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors.
    Harmsen S; Meijerman I; Maas-Bakker RF; Beijnen JH; Schellens JH
    Eur J Pharm Sci; 2013 Mar; 48(4-5):644-9. PubMed ID: 23277288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
    Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
    Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters.
    Schneiderman RS; Shmueli E; Kirson ED; Palti Y
    BMC Cancer; 2010 May; 10():229. PubMed ID: 20492723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
    Nagashima S; Soda H; Oka M; Kitazaki T; Shiozawa K; Nakamura Y; Takemura M; Yabuuchi H; Fukuda M; Tsukamoto K; Kohno S
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):594-600. PubMed ID: 16520985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A; Wiese M
    ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance.
    Shi Z; Parmar S; Peng XX; Shen T; Robey RW; Bates SE; Fu LW; Shao Y; Chen YM; Zang F; Chen ZS
    Oncol Rep; 2009 Feb; 21(2):483-9. PubMed ID: 19148526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
    D'Cunha R; Bae S; Murry DJ; An G
    Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
    Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B
    Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.
    Tiwari AK; Sodani K; Wang SR; Kuang YH; Ashby CR; Chen X; Chen ZS
    Biochem Pharmacol; 2009 Jul; 78(2):153-61. PubMed ID: 19427995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vandetanib (Zactima, ZD6474) antagonizes ABCC1- and ABCG2-mediated multidrug resistance by inhibition of their transport function.
    Zheng LS; Wang F; Li YH; Zhang X; Chen LM; Liang YJ; Dai CL; Yan YY; Tao LY; Mi YJ; Yang AK; To KK; Fu LW
    PLoS One; 2009; 4(4):e5172. PubMed ID: 19390592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.
    Yamazaki R; Nishiyama Y; Furuta T; Hatano H; Igarashi Y; Asakawa N; Kodaira H; Takahashi H; Aiyama R; Matsuzaki T; Yagi N; Sugimoto Y
    Mol Cancer Ther; 2011 Jul; 10(7):1252-63. PubMed ID: 21566063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
    Grundy M; Seedhouse C; Russell NH; Pallis M
    BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.